A disease that kills more than 600,000 people annually—roughly the same death toll as HIV/AIDS and malaria combined—is finally receiving the investment it has lacked for more than a century. Coefficient Giving announced the launch of the Strep A Vaccine Fund this week, a multi-donor initiative that has already raised just over $140 million toward a $200 million goal, with backing from Good Ventures, Lucy Southworth, Adam and Abigail Winkel, and other anchor funders.
For most people in wealthy countries, Strep A conjures images of childhood strep throat—painful but treatable with antibiotics. The real devastation happens elsewhere. In low- and middle-income countries, repeated Strep A infections trigger rheumatic heart disease (RHD), a condition where the immune system misfires and permanently damages heart valves. Today, roughly 55 million people live with RHD. Without access to monthly penicillin injections or heart valve surgery—treatments largely unavailable where the disease is most common—advanced RHD is often fatal. The disease clusters among children and adolescents in overcrowded housing with limited sanitation, making it overwhelmingly a disease of poverty.
What makes this moment significant is not the problem itself, but the sudden shift in resources and coordination. "In more than a decade of evaluating causes, we've rarely seen a problem this neglected relative to its scale," said Alexander Berger, CEO of Coefficient Giving. Scientists have been working toward a Strep A vaccine for decades on minimal funding, yet important progress has been made—including a human challenge trial model that could accelerate testing. The missing piece has been sustained investment and strategic coordination.
The Fund will operate across the full vaccine development pathway. It will accelerate existing vaccine candidates through clinical trials, seed next-generation candidates using the most modern vaccine design technology, back foundational research to improve development methods, prepare deployment infrastructure in advance to prevent delays, and strengthen community coordination networks. Coefficient has already made early grants to support two promising vaccine candidates from early-stage testing, improved production methods for key vaccine components, and AI-powered algorithms for detecting RHD through ultrasound images.
This approach mirrors lessons learned from recent vaccine development successes. Rather than betting everything on a single candidate, the Fund will test multiple approaches in parallel and prepare each development stage well in advance—a strategy that proved effective for malaria and COVID-19 vaccines. Katharine Collins, senior program officer at Coefficient Giving and leader of the Fund, noted that decades of limited funding had constrained what researchers could accomplish. Now, with coordinated investment and modern vaccine technology at their disposal, the pathway to protection looks genuinely within reach.
The Strep A Vaccine Fund reflects Coefficient Giving's broader model of collaborative, cost-effective philanthropy. Since 2014, the organization has directed more than $5 billion in grants across more than a dozen cause areas, identifying where philanthropic capital can have the greatest impact. This latest initiative joins other multi-donor funds, including the $120 million Abundance & Growth Fund and the $125 million Lead Exposure Action Fund, in demonstrating that strategic coordination among funders can unlock progress on problems once thought intractable.